MacroGenics (NASDAQ:MGNX) is scheduled to be announcing its earnings results after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of $2.62 per share for the quarter.
MacroGenics (NASDAQ:MGNX) opened at $23.46 on Friday. The firm has a market cap of $846.55, a price-to-earnings ratio of -5.21 and a beta of 2.80. MacroGenics has a one year low of $14.36 and a one year high of $24.26.
A number of equities analysts recently weighed in on MGNX shares. BidaskClub raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 25th. Citigroup increased their price objective on shares of MacroGenics from $18.00 to $22.00 and gave the stock a “neutral” rating in a research note on Friday, November 10th. BTIG Research restated a “buy” rating and set a $28.00 price objective on shares of MacroGenics in a research note on Tuesday, January 23rd. ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $30.60.
In other news, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $22.50, for a total transaction of $67,500.00. Following the completion of the sale, the senior vice president now directly owns 12,100 shares in the company, valued at $272,250. The disclosure for this sale can be found here. Corporate insiders own 8.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “MacroGenics (MGNX) Set to Announce Quarterly Earnings on Monday” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/24/macrogenics-mgnx-set-to-announce-quarterly-earnings-on-monday.html.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.